Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations-Reference-Cited by-同舟云学术

Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations

Published:2014-01-24 Issue:6 Volume:34 Page:e1-e9
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Mellor Howard R.¹

Affiliation:

1. Drug Safety & Metabolism; Innovative Medicines; AstraZeneca R&D; Macclesfield UK

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12462/fullpdf

Reference60 articles.

1. Fibroblast growth factor signalling: from development to cancer;Turner;Nat Rev Cancer,2010

2. Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early Xenopus embryo;Kimelman;Cell,1987

3. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1;McWhirter;Development,1997

4. Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors;Wiedemann;Genomics,2000

5. Fibroblast growth factors and their receptors in cancer;Wesche;Biochem J,2011

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine;International Journal of Molecular Sciences;2024-01-26

2. Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis;Journal of Computer-Aided Molecular Design;2023-06-03

3. RNA-seq of hypo- and hyper-salinity stress-response transcriptome in the liver of greater amberjack (Seriola dumerili) juveniles;Aquaculture Reports;2023-04

4. Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients;Cancer Medicine;2023-01-09

5. Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model‐Informed Dose Selection in Oncology First‐in‐Human Study: A Case of Roblitinib ( FGF401 );Clinical Pharmacology & Therapeutics;2022-10-18